Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This study will combine the chemotherapy agent temozolomide with the investigational drug
SCH66336 (an agent which interferes with new cell growth). Patients will be treated with oral
temozolomide on days 1-5 and oral SCH66336 on days 8-28 every 28 days.